Alzheimer's Disease Pathogenesis represents the complex series of molecular and cellular events that lead to neurodegeneration in Alzheimer's disease (AD). This page provides a comprehensive mechanistic model integrating amyloid biology, tau pathology, neuroinflammation, synaptic dysfunction, metabolic disturbances, and genetic risk factors into a unified framework for understanding disease progression and identifying therapeutic targets.
Alzheimer's disease is the most common cause of dementia, affecting over 55 million people worldwide. The pathogenesis of AD involves multiple interconnected mechanisms that work together to cause progressive neurodegeneration, beginning decades before clinical symptoms appear. The amyloid cascade hypothesis remains the dominant framework, but contemporary models recognize the complexity of bidirectional relationships between amyloid, tau, neuroinflammation, and synaptic loss.
- Prevalence: 6.5 million Americans aged 65+ (2023)
- Disease duration: Typically 10-20 years from pathology onset to symptoms
- Brain weight loss: Up to 20% reduction in advanced cases
- Economic burden: $345 billion annually in the US (2023)
Amyloid-beta peptides are produced through proteolytic cleavage of the Amyloid Precursor Protein (APP), a type I transmembrane protein of unknown physiological function. APP can be processed through two major pathways:
Non-amyloidogenic pathway:
APP → α-secretase → sAPPα → carboxyterminal fragment (CTF) → γ-secretase → p3 peptide
Amyloidogenic pathway (Aβ production):
APP → BACE → sAPPβ → CTF99 → γ-secretase → Aβ peptides (Aβ40, Aβ42)
BACE1 (β-secretase) performs the rate-limiting step in amyloid production, cleaving APP at the N-terminus of the Aβ sequence. γ-secretase (a complex of PSEN1, PSEN2, NCT, APH-1, PEN-2) performs the final cleavage, generating Aβ peptides of varying lengths. Aβ42 is more aggregation-prone than Aβ40 and is the primary species found in plaques.
Aβ peptides undergo a conformational transition from random coil to β-sheet structure, leading to:
- Oligomerization: Soluble Aβ oligomers (synaptotoxic)
- Protofibril formation: Intermediate aggregation species
- Fibril elongation: Mature amyloid fibrils
- Plaque deposition: Dense core plaques, diffuse plaques
- Synaptic dysfunction: Aβ oligomers bind to prion protein (PrP^C) and disrupt synaptic signaling
- Oxidative stress: Metal-catalyzed ROS generation
- Calcium dysregulation: Membrane pore formation, receptor dysregulation
- Mitochondrial dysfunction: Complex IV inhibition, ATP depletion
- Inflammation activation: NLRP3 inflammasome activation in microglia
Tau is a microtubule-associated protein that stabilizes neuronal axons. In AD, tau becomes abnormally hyperphosphorylated, leading to loss of function and gain of toxic properties.
Over 40 serine/threonine phosphorylation sites have been identified on tau in AD brain. Key sites include:
- Ser202/Thr205 (AT8 epitope) - early marker
- Ser396/Ser404 (PHF1 epitope) - disease progression marker
- Thr181 - biomarker candidate
Multiple kinases contribute to tau hyperphosphorylation:
- GSK-3β: Primary kinase, tau kinase activity increased in AD
- CDK5: Activated by p25/p35, hyperphosphorylates tau
- MAPK family: ERK1/2, JNK, p38
- CK2 (Casein Kinase 2): Phosphorylates multiple sites
PP2A (Protein Phosphatase 2A) accounts for ~70% of tau phosphatase activity in brain. PP2A activity is reduced in AD through:
- Methylation defects (PME)
- Inhibitory phosphorylation (Tyr307)
- Endogenous inhibitors (I1PP2A, I2PP2A)
Hyperphosphorylated tau dissociates from microtubules, leading to:
- Microtubule destabilization and transport defects
- Tau oligomerization in cytosol
- Paired helical filament (PHF) formation
- Neurofibrillary tangle accumulation
- Neuronal death and Braak staging progression
Chronic neuroinflammation is a hallmark of AD, with microglial and astrocyte activation observed throughout disease progression.
- Homeostatic microglia: Survey brain parenchyma, ramified morphology
- Disease-associated microglia (DAM): Triggered by Aβ and tau, clustered around plaques
- Neurodegenerative microglia (NG): Found in regions of neuronal loss
| Mediator |
Source |
Effect |
| IL-1β |
Microglia |
Promotes tau pathology, synaptic dysfunction |
| TNF-α |
Microglia/Astrocytes |
Synaptic pruning, neuronal death |
| IL-6 |
Astrocytes |
Acute phase response, inhibits neurogenesis |
| IL-18 |
Microglia |
IFN-γ dependent, promotes inflammation |
| TGF-β |
Various |
Modulates microglial phenotype |
- C1q: Initiates classical complement, tags synapses for elimination
- C3/C3R: Critical for microglial phagocytosis
- C5a: Pro-inflammatory anaphylatoxin
Synaptic loss is the strongest correlate of cognitive impairment in AD, occurring before neuron loss.
- Synaptic vesicle depletion: Reduced readily-releasable pool
- Release probability changes: Impaired short-term plasticity
- Calcium handling defects: Reduced synaptotagmin-1 function
- AMPA receptor trafficking: Reduced surface expression
- NMDA receptor dysregulation: Altered subunit composition
- mGluR5 hyperactivity: Calcium dysregulation
- GABAergic dysfunction: Inhibitory/excitatory imbalance
- Spine density reduction: 25-45% loss in AD hippocampus
- Spine morphology changes: Loss of mushroom spines
- Synaptic size reduction: Smaller active zones
AD is increasingly recognized as a metabolic disorder affecting brain glucose metabolism.
- Reduced FDG-PET signal: 20-40% in posterior cingulate
- Cause: Mitochondrial dysfunction, insulin resistance
- Consequence: ATP deficits, impaired neurotransmission
Brain insulin resistance involves:
- IRS-1 serine phosphorylation: Inhibitory phosphorylation at Ser636
- PI3K/Akt signaling defects: Reduced downstream signaling
- Akt activity reduction: Impaired tau phosphorylation control
- Complex IV inhibition: By Aβ and oxidative stress
- mtDNA mutations: Accumulation with age
- Dynamics defects: Impaired fission/fusion
- Mitophagy impairment: Reduced clearance of damaged mitochondria
The relationship between amyloid and tau is bidirectional:
graph TD
A[APP Processing]|Increased| B[Aβ Production] -->
B --> C[Aβ Oligomers] -->
C --> D[Synaptic Dysfunction)
C --> E[Microglial Activation] -->
E --> F[Chronic Inflammation] -->
F --> G[Tau Kinase Activation] -->
G --> H[Tau Hyperphosphorylation)
H --> I[NFT Formation] -->
I --> J[Neuronal Loss] -->
D --> J
B -->|Prion-like| I
graph LR
A[Aβ Plaques] --> B[Microglial Activation] -->
B --> C[NLRP3 Inflammasome)
C --> D[IL-1β Release] -->
D --> E[Neural Circuit Dysfunction] -->
E --> F[Cognitive Decline] -->
B --> G[Complement Activation] -->
G --> H[Synaptic Pruning] -->
H --> E
| Gene |
Chromosome |
Function |
Mutations |
| APP |
21q21 |
Amyloid precursor protein |
40+ pathogenic mutations |
| PSEN1 |
14q24.3 |
γ-secretase component |
200+ mutations |
| PSEN2 |
1q42.13 |
γ-secretase component |
40+ mutations |
APOE (apolipoprotein E) is the major genetic risk factor for sporadic AD:
| Allele |
Frequency |
AD Risk |
Mechanism |
| ε3 |
77% |
Baseline |
Normal function |
| ε4 |
14% |
3-4x increased |
Reduced Aβ clearance, impaired repair |
| ε2 |
8% |
Reduced |
Enhanced clearance |
APOE4 effects:
- Reduced Aβ clearance across BBB
- Enhanced Aβ aggregation
- Impaired synaptic plasticity
- Increased tau pathology
- Microglial phenotype shifts
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) variants increase AD risk ~3-fold:
- R47H: Reduces ligand binding
- R62H: Impaired signaling
- TREM2 KO: Reduced microglial clustering around plaques
- Lecanemab (Leqembi): Clears Aβ plaques, FDA approved 2023
- Donanemab: Phase 3 positive, removes amyloid and slows progression
- Aduhelm (withdrawn): First anti-Aβ antibody
- Antisense oligonucleotides: Reduce tau expression
- Kinase inhibitors: GSK-3β, CDK5 modulators
- Tau aggregation inhibitors: Methylene blue derivatives
- TREM2 agonists: Enhance microglial function
- CSF1R antagonists: Reduce microglial proliferation
- NLRP3 inhibitors: Block inflammasome activation
| Target |
Drug Class |
Examples |
| Cholinergic |
AChE inhibitors |
Donepezil, Rivastigmine, Galantamine |
| Glutamatergic |
NMDA antagonist |
Memantine |
| Neuropsychiatric |
Various |
Antidepressants, antipsychotics |
- Aβ42/40 ratio: Reduced in CSF (plasma now available)
- Total tau: Elevated in CSF
- Phospho-tau (Thr181): Elevated in CSF/plasma
- Neurofilament light (NfL): Axonal damage marker
- Amyloid PET: Florbetapir, Florbetaben
- Tau PET: Flortaucipir
- FDG-PET: Hypometabolism patterns
- MRI: Atrophy patterns
Alzheimer's disease pathogenesis involves a complex interplay of amyloid accumulation, tau pathology, neuroinflammation, synaptic dysfunction, and metabolic disturbances. While the amyloid cascade hypothesis remains influential, current models emphasize the multi-hit nature of AD and the bidirectional relationships between pathological features. Understanding these mechanisms is crucial for developing effective therapies that target multiple pathways simultaneously.
The study of Alzheimer'S Disease Pathogenesis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-356.
- Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595-608.
- Heneka MT, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-405.
- De Strooper B, Karran E. The cellular phase of Alzheimer's disease. Cell. 2016;164(4):603-615.
- Wang J, et al. Tau propagation as a diagnostic and therapeutic target for dementia. Nat Rev Neurol. 2019;15(12):735-751.
- Serrano-Pozo A, et al. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189.
- Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362(4):329-344.
- Calsolaro V, Edison P. Neuroinflammation in Alzheimer's disease: Current evidence and future directions. Alzheimer's Dement. 2016;12(6):719-732.
- Hampel H, et al. The amyloid-β pathway in Alzheimer's disease. Mol Psychiatry. 2021;26(10):5481-5503.
- Scheltens P, et al. Alzheimer's disease. Lancet. 2016;388(10043):505-517.
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
10 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 31%